Assess whether regulatory approval is a timing risk or a deal risk (b975ff)
August 31, 2026
SITUATION A strategic buyer looking at a carve-out from a conglomerate cannot treat a TSA that expires before replacement systems exist as incidental context on QoE add-backs the seller marked 'normalized'. IP diligence counsel's financial counterpart must close regulatory approval is a from that extract under M&A Due Diligence / Earnings and Revenue Quality.
DECISION IP diligence counsel's financial counterpart in a strategic buyer looking at a carve-out from a conglomerate must choose Regulatory approval is a timing risk / A deal risk using QoE add-backs the seller marked 'normalized' after a TSA that expires before replacement systems exist.
HYPOTHESES TO TEST 1. The population in QoE add-backs the seller marked 'normalized' is the one a TSA that expires before replacement systems exist named, so Regulatory approval is a timing risk follows for this Earnings and Revenue Quality file. 2. The population in QoE add-backs the seller marked 'normalized' is adjacent only to a TSA that expires before replacement systems exist; A deal risk is the honest M&A Due Diligence call. 3. A strategic buyer looking at a carve-out from a conglomerate already contained a TSA that expires before replacement systems exist before QoE add-backs the seller marked 'normalized' arrived; no new Earnings and Revenue Quality path. 4. Provenance on QoE add-backs the seller marked 'normalized' after a TSA that expires before replacement systems exist is broken; do not pick Regulatory approval is a timing risk or A deal risk yet.
ANALYSIS REQUIRED 1. Test whether a TSA that expires before replacement systems exist is a diligence gap, a price chip, or a walk-away. 2. Separate a one-off add-back from a recurring earnings issue in QoE add-backs the seller marked 'normalized'. 3. Map reps, earnout mechanics, and integration risk a strategic buyer looking at a carve-out from a conglomerate would inherit. 4. For this M&A Due Diligence Earnings and Revenue Quality file, read QoE add-backs the seller marked 'normalized' against a TSA that expires before replacement systems exist and write the one fact that would move regulatory approval is a for IP diligence counsel's financial counterpart.
RECOMMENDATION Choose Regulatory approval is a timing risk / A deal risk on this M&A Due Diligence / Earnings and Revenue Quality packet (QoE add-backs the seller marked 'normalized' after a TSA that expires before replacement systems exist). Lead with the M&A Due Diligence option QoE add-backs the seller marked 'normalized' can support after a TSA that expires before replacement systems exist, then the two facts that force it, then the Monday action for IP diligence counsel's financial counterpart in a strategic buyer looking at a carve-out from a conglomerate.
Explore more
More M&A Due Diligence prompts
- Whether the carve-out is operable on day one from QoE add-backs the seller
- Assess whether related-party sales should be backed out of valuation (f0ea67)
- Assess whether related-party sales should be backed out of valuation (f05865)
- Assess whether management can run this without the founder from earnout
- Working-capital true-up analyst must resolve whether earnout definitions will
Explore related decision areas
- Assess whether Section M scoring math was applied consistently (d52bfd)Government RFP
- Assess whether CAT pricing is defensible given SOV quality (376886)Insurance Underwriting
- Assess whether SAB 99 qualitative materiality is triggered (144709)Forensic Accounting
See governed multi-model AI on your own prompt
Compare GPT-5, Claude, and Gemini side by side, with human review and a decision record built in.

